United Therapeutics stock is trading -27.52% below its average target price of $389.48 after dropping -14.0% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $314.0 to $600.0 per share.
The stock has an average amount of shares sold short at 6.1%, and a short ratio of 4.81. The company's insiders own 1.82% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 101.4% of United Therapeutics's shares being owned by this investor type.
Institutions Invested in United Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Blackrock Inc. | 12% | 5,446,092 | $1,537,380,016 |
| 2025-03-31 | Vanguard Group Inc | 10% | 4,457,135 | $1,258,206,853 |
| 2025-03-31 | Avoro Capital Advisors LLC | 6% | 2,675,000 | $755,127,079 |
| 2025-03-31 | State Street Corporation | 5% | 2,230,708 | $629,707,669 |
| 2025-03-31 | Renaissance Technologies, LLC | 5% | 2,106,992 | $594,783,818 |
| 2025-03-31 | Wellington Management Group, LLP | 4% | 2,026,416 | $572,037,979 |
| 2025-03-31 | Geode Capital Management, LLC | 3% | 1,223,993 | $345,521,592 |
| 2025-03-31 | FMR, LLC | 3% | 1,144,603 | $323,110,549 |
| 2025-03-31 | AQR Capital Management, LLC | 2% | 908,448 | $256,446,237 |
| 2025-03-31 | LSV Asset Management | 2% | 902,323 | $254,717,207 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on United Therapeutics.
